Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Equity Average (2016 - 2025)

Historic Equity Average for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $187.6 million.

  • Regenxbio's Equity Average fell 4225.94% to $187.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.6 million, marking a year-over-year decrease of 4225.94%. This contributed to the annual value of $285.7 million for FY2024, which is 3098.59% down from last year.
  • Regenxbio's Equity Average amounted to $187.6 million in Q3 2025, which was down 4225.94% from $243.9 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Equity Average ranged from a high of $727.0 million in Q1 2022 and a low of $187.6 million during Q3 2025
  • Its 5-year average for Equity Average is $436.4 million, with a median of $435.5 million in 2023.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 5596.2% in 2022, then plummeted by 4225.94% in 2025.
  • Regenxbio's Equity Average (Quarter) stood at $612.9 million in 2021, then dropped by 11.89% to $540.0 million in 2022, then tumbled by 37.52% to $337.4 million in 2023, then decreased by 16.86% to $280.5 million in 2024, then crashed by 33.14% to $187.6 million in 2025.
  • Its last three reported values are $187.6 million in Q3 2025, $243.9 million for Q2 2025, and $266.9 million during Q1 2025.